Pregnant women and infants are at risk should they contract mpox but there are no approved vaccines for this population.

The World Health Organisation declared mpox a global health emergency in mid-August, after a new strain began spreading from ...

A spokesperson for Bavarian Nordic said 265,000 doses of its mpox vaccine, Jynneos, had been delivered to African countries, ...

A clinical trial by the US National Institutes of Health (NIH) has shown that Bavarian Nordic’s mpox vaccine induced an antibody response in adolescents equivalent to that of adults. The interim ...

While Bavarian Nordic’s vaccine Jynneos is approved in several countries to prevent mpox and smallpox infections in adults, there has been a lack of data to support its approval in adolescents.

Emergent and Bavarian Nordic have both said they are ready and ... "The increasing outbreaks of mpox around the world should raise concerns and spur ongoing efforts to produce and stockpile ...

An independent study has found that Bavarian Nordic's mpox vaccine Jynneos – currently only authorised for use in adults in the US – is also safe and generates a strong antibody response in ...

The World Health Organisation said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

An initial 899,000 vaccine doses have been allocated for nine countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organizations say.

COPENHAGEN, Denmark, October 29, 2024 - Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ® mpox/smallpox vaccine in children 2 to 11 years of age.

Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase III trial (PregInPoxVac) will enrol around 350 pregnant women ...